
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune Inc. has demonstrated promising clinical results for its investigational drug pemvidutide, showcasing weight loss of up to 6.2% over 24 weeks and significant liver fat reduction of 62.8%, alongside compelling anti-fibrotic activity indicated by improvements in biomarker and histological measures. The recent positive developments in the metabolic dysfunction field, highlighted by Novo's acquisition of Akero Therapeutics, underscore a growing market for treatments like pemvidutide that may offer a simplified approach to metabolic diseases without the complexities of combination therapies. Furthermore, the strengthening of Altimmune’s leadership team in preparation for upcoming pivotal trials enhances confidence in pemvidutide’s potential as a best-in-class therapy for obesity and metabolic-associated steatohepatitis (MASH).
Bears say
Altimmune Inc has experienced a significant decline in its stock price, falling approximately 55%, despite the development of its promising product candidate, pemvidutide. The company's outlook is marred by numerous risks associated with clinical development, competition, commercialization, and reimbursement, among others, which cumulatively contribute to a cautious financial perspective. Furthermore, potential disruptions from external factors such as COVID-19 and geopolitical tensions in Eastern Europe may further complicate clinical trial timelines and overall business operations, heightening the uncertainty surrounding Altimmune's future market performance.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares